# A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)

Source: https://onco.cc/trials/nct02441309/  
OnCo record `nct02441309` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mifamurtide and Ifosfamide in Osteosarcoma, run by University of Oxford, recorded as terminated on the registry.

## Summary

A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) is a phase 2 interventional study registered as NCT02441309 by University of Oxford, with 8 participants recorded, started 2014-10 and due to reach its primary completion in 2016-11-04. Interventions recorded: Mifamurtide, Ifosfamide. Conditions recorded: Osteosarcoma.

Linked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02441309
- Phase: 2
- Setting: A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma
- Sponsor: University of Oxford
- Enrolled: 8

## Sources

- ClinicalTrials.gov NCT02441309: https://clinicaltrials.gov/study/NCT02441309

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Ifosfamide](https://onco.cc/drugs/ifosfamide/), [Mifamurtide](https://onco.cc/drugs/mifamurtide/)

---
JSON: https://onco.cc/api/v1/entities/nct02441309.json